PeppyWiki research guide
A plain-language snapshot of every named entry currently selectable in the PeppyCalc calculator — what it is, what researchers are investigating, whether humans have been studied, and how established the evidence is.
What it is: Small-molecule NNMT inhibitor; not technically a peptide.
What it is being researched for: Investigated preclinically for metabolism, fat accumulation and energy balance.
What it is: AMPK-activating research compound; not a peptide.
What it is being researched for: Studied for cellular energy sensing, glucose metabolism and exercise-like metabolic signalling.
What it is: Experimental targeted peptidomimetic designed to affect blood vessels supplying fat tissue.
What it is being researched for: Studied as a possible way to reduce adipose tissue.
What it is: Synthetic peptide derived from erythropoietin signalling, designed to avoid red-blood-cell stimulation.
What it is being researched for: Studied for tissue protection, neuropathic pain and inflammatory injury.
What it is: Synthetic peptide based on a gastric-protein fragment.
What it is being researched for: Promoted for tendon, ligament, muscle and gut repair; most evidence remains experimental.
What it is: Melanocortin receptor agonist peptide drug.
What it is being researched for: Used clinically for acquired, generalized hypoactive sexual desire disorder in certain premenopausal women; also researched for sexual-function effects.
What it is: Long-acting amylin analogue.
What it is being researched for: Investigated for appetite regulation, obesity and weight management, including combinations with GLP-1 therapies.
What it is: Research entry for Cartalax.
What it is being researched for: Studied or marketed for biological-regulation, recovery, metabolic, immune or tissue effects; reliable clinical evidence is limited.
What it is: Mixture of low-molecular-weight peptides and amino acids derived from porcine brain tissue.
What it is being researched for: Used or studied in some countries for stroke, traumatic brain injury and cognitive disorders; evidence and approvals vary by country.
What it is: Long-acting growth-hormone-releasing-hormone analogue.
What it is being researched for: Investigated for increasing growth hormone and IGF-1 signalling.
What it is: Shorter-acting GHRH analogue commonly sold as a research peptide.
What it is being researched for: Intended to stimulate endogenous growth-hormone release.
What it is: Research blend combining a GHRH analogue with a ghrelin-receptor agonist.
What it is being researched for: Marketed to increase pulsatile growth-hormone release.
What it is: Research entry for Cortagen.
What it is being researched for: Studied or marketed for biological-regulation, recovery, metabolic, immune or tissue effects; reliable clinical evidence is limited.
What it is: Research entry for Crystagen.
What it is being researched for: Studied or marketed for biological-regulation, recovery, metabolic, immune or tissue effects; reliable clinical evidence is limited.
What it is: Experimental small peptide-like compound derived from angiotensin IV research.
What it is being researched for: Studied preclinically for synapse formation, cognition and neurodegenerative disease.
What it is: Delta sleep-inducing peptide.
What it is being researched for: Studied historically for sleep, stress and neuroendocrine effects, but evidence is inconsistent.
What it is: Synthetic tetrapeptide associated with Russian bioregulator research.
What it is being researched for: Promoted for ageing, circadian rhythm and telomerase-related effects.
What it is: Research entry for Epobis.
What it is being researched for: Studied or marketed for biological-regulation, recovery, metabolic, immune or tissue effects; reliable clinical evidence is limited.
What it is: Form of follistatin, a protein that binds activins and myostatin-related signals.
What it is being researched for: Investigated for muscle growth and muscle-wasting conditions.
What it is: Experimental cell-penetrating peptide intended to disrupt FOXO4-p53 interactions.
What it is being researched for: Studied as a senolytic approach to selectively remove senescent cells.
What it is: Fragment corresponding to the C-terminal region of human growth hormone.
What it is being researched for: Marketed for fat-metabolism effects without full growth-hormone activity.
What it is: Experimental inhibitor/modulator of myostatin signalling.
What it is being researched for: Studied for increasing muscle mass or treating muscle-wasting disorders.
What it is: Naturally occurring copper-binding tripeptide.
What it is being researched for: Studied for skin remodelling, wound healing, hair biology and tissue repair.
What it is: Synthetic growth-hormone secretagogue acting at the ghrelin receptor.
What it is being researched for: Studied for stimulating growth-hormone release and appetite/metabolic effects.
What it is: Synthetic ghrelin-receptor agonist and growth-hormone secretagogue.
What it is being researched for: Studied for growth-hormone release, appetite and metabolic effects.
What it is: Synthetic gonadotropin-releasing hormone (GnRH).
What it is being researched for: Used diagnostically and therapeutically in some settings to stimulate LH and FSH release.
What it is: Naturally occurring glycoprotein hormone used as a medicine; not a peptide in the narrow sense.
What it is being researched for: Used in fertility care and selected endocrine indications.
What it is: Synthetic growth-hormone secretagogue.
What it is being researched for: Studied for GH release and possible cardiovascular/metabolic effects.
What it is: Recombinant human growth hormone.
What it is being researched for: Used for approved growth-hormone deficiency and other specific medical indications.
What it is: C-terminal fragment of human growth hormone.
What it is being researched for: Studied and marketed for lipolysis/fat-metabolism effects.
What it is: Mitochondria-derived peptide.
What it is being researched for: Investigated for cellular stress resistance, metabolism, ageing and neuroprotection.
What it is: Shortened insulin-like growth factor-1 analogue.
What it is being researched for: Studied for local growth and anabolic signalling.
What it is: Long-acting IGF-1 analogue used in research.
What it is being researched for: Investigated for growth, metabolism and tissue-anabolic signalling.
What it is: Selective ghrelin-receptor agonist and growth-hormone secretagogue.
What it is being researched for: Studied for stimulating growth-hormone release.
What it is: Short active fragment of kisspeptin, a regulator of the reproductive axis.
What it is being researched for: Studied for triggering GnRH/LH release, fertility and reproductive endocrinology.
What it is: Longer kisspeptin form with reproductive-hormone activity.
What it is being researched for: Studied for fertility treatment, ovulation triggering and reproductive endocrinology.
What it is: Research blend containing GHK-Cu, BPC-157, TB-500-related material and KPV.
What it is being researched for: Marketed for recovery, inflammation and tissue-repair claims.
What it is: Tripeptide fragment derived from alpha-MSH.
What it is being researched for: Studied for anti-inflammatory effects in skin, gut and immune models.
What it is: Human antimicrobial host-defence peptide.
What it is being researched for: Studied for antimicrobial activity, immunity, wound healing and inflammation.
What it is: Melanocortin analogue; afamelanotide is a regulated implant medicine in some jurisdictions.
What it is being researched for: Used to increase protective eumelanin in specific photosensitivity disorders; also related to tanning research.
What it is: Synthetic melanocortin receptor agonist.
What it is being researched for: Studied for pigmentation, sexual-function and appetite effects.
What it is: Mechano growth factor, an IGF-1 splice-variant-related peptide concept.
What it is being researched for: Promoted for muscle repair and growth after mechanical loading.
What it is: Mitochondria-derived peptide involved in metabolic signalling.
What it is being researched for: Investigated for insulin sensitivity, exercise metabolism, ageing and metabolic disease.
What it is: Cellular redox cofactor; not a peptide.
What it is being researched for: Used in metabolism and energy-transfer pathways; supplemental/infusion claims extend beyond established evidence.
What it is: Modified Semax analogue sold for research use.
What it is being researched for: Marketed for cognitive, neuroprotective and nootropic effects.
What it is: Modified Selank analogue sold for research use.
What it is being researched for: Marketed for anxiolytic, cognitive and stress-related effects.
What it is: Naturally occurring peptide hormone and approved medicine.
What it is being researched for: Used clinically for labour induction/augmentation and postpartum bleeding management; also researched for social and behavioural effects.
What it is: Experimental peptide derived from a region of ciliary neurotrophic factor.
What it is being researched for: Studied preclinically for neurogenesis, cognition and neuroprotection.
What it is: Experimental peptide associated with neurotrophic/antidepressant research.
What it is being researched for: Promoted for mood, neuroplasticity and cognitive effects.
What it is: PEGylated research version of mechano growth factor.
What it is being researched for: Marketed for prolonged muscle-repair or anabolic signalling.
What it is: Research entry for Pinealon.
What it is being researched for: Studied or marketed for biological-regulation, recovery, metabolic, immune or tissue effects; reliable clinical evidence is limited.
What it is: Experimental anticancer peptide derived from p53-related sequences.
What it is being researched for: Studied for selectively damaging certain cancer-cell membranes.
What it is: Triple agonist targeting GIP, GLP-1 and glucagon receptors.
What it is being researched for: Being developed for obesity and metabolic disease, with substantial weight-loss effects observed in human trials.
What it is: Synthetic peptide related to the immunomodulatory peptide tuftsin.
What it is being researched for: Studied and marketed for anxiety, stress and cognitive effects.
What it is: GLP-1 receptor agonist peptide medicine.
What it is being researched for: Approved for type 2 diabetes, chronic weight management and selected cardiovascular/kidney/liver-related indications depending on product and jurisdiction.
What it is: Synthetic ACTH-fragment analogue developed as a neuroactive peptide.
What it is being researched for: Studied for neuroprotection and cognitive effects; regional medical-use claims differ.
What it is: GHRH(1-29) analogue that stimulates growth-hormone release.
What it is being researched for: Studied/used historically to assess or stimulate endogenous GH secretion.
What it is: Mitochondria-targeting tetrapeptide.
What it is being researched for: Investigated for mitochondrial dysfunction, cardiomyopathy, kidney disease and rare mitochondrial disorders.
What it is: Dual glucagon/GLP-1 receptor agonist.
What it is being researched for: Investigated for obesity and metabolic liver disease.
What it is: TB-500 is a research product associated with thymosin beta-4 biology.
What it is being researched for: Promoted for wound healing, tissue repair and recovery; claims often extrapolate from thymosin beta-4 research.
What it is: Synthetic GHRH analogue.
What it is being researched for: Approved to reduce excess abdominal visceral fat in adults with HIV-associated lipodystrophy; also researched in metabolic/liver contexts.
What it is: Monoamine reuptake inhibitor; not a peptide.
What it is being researched for: Investigated as an anti-obesity drug because of appetite and weight effects.
What it is: Research entry for Thymalin.
What it is being researched for: Studied or marketed for biological-regulation, recovery, metabolic, immune or tissue effects; reliable clinical evidence is limited.
What it is: Immune-modulating thymic peptide also called thymalfasin.
What it is being researched for: Studied or used in some countries for immune modulation, infections and as an adjunct in selected conditions.
What it is: Dual GIP/GLP-1 receptor agonist peptide medicine.
What it is being researched for: Approved for type 2 diabetes and chronic weight management, with ongoing studies in additional metabolic conditions.
What it is: Long-acting GnRH agonist peptide medicine.
What it is being researched for: Used for hormone-sensitive conditions such as prostate cancer and other endocrine/reproductive indications depending on product.
What it is: Naturally occurring neuropeptide with vascular, pulmonary and immune effects.
What it is being researched for: Studied for pulmonary, inflammatory and neurologic conditions; synthetic analogues have been investigated clinically.